27 -8 (58) 2023 — Nuritdinov N.A., Agzamkhodzhaeva S.Sh. — NON-ALCOHOLIC FATTY LIVER DISEASE AS A PREDICTOR OF CARDIOVASCULAR DISEASES

NON-ALCOHOLIC FATTY LIVER DISEASE AS A PREDICTOR OF CARDIOVASCULAR DISEASES

Nuritdinov N.A., Tashkent Medical Academy

Agzamkhodzhaeva S.Sh. Tashkent Medical Academy

Resume

This review provides data on the association of non-alcoholic fatty liver disease (NAFLD) with cardiovascular disease (CVD). Most studies suggest that NAFLD is associated with an increase in CVD. The risk of developing CVD increases as liver disease progresses. NAFLD is an independent factor contributing to the development and progression of CVD. The pathogenetic mechanisms of the relationship between cardiovascular diseases and non-alcoholic fatty liver disease are described.

Keywords: non-alcoholic fatty liver disease, cardiovascular risk, atherosclerosis, humoral factors

First page

159

Last page

164

For citation: Nuritdinov N.A., Agzamkhodzhaeva S.Sh. – NON-ALCOHOLIC FATTY LIVER DISEASE AS A PREDICTOR OF CARDIOVASCULAR DISEASES //New Day in Medicine 2023 8(58): 159-164 https://newdaymedicine.com/index.php/2023/08/19/l-315/

LIST OF REFERENCES:

1. Ахмедов В.А. Взаимосвязь сердечно-сосудистых осложнений и неалкогольной жировой болезни печени. РМЖ. 2018;1(II):86-88.
2. Гарбузенко Д.В., Белов Д.В. Неалкогольная жировая болезнь печени как независимый фактор кардиометаболического риска сердечно-сосудистых заболеваний. Экспериментальная и клиническая гастроэнтерология. 2021;(10):22-34. 
3. Драпкина О.М., Яфарова А.А. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: состояние проблемы. Рациональная фармакотерапия в кардиологии 2017;13(5):645-650. DOI: 10.20996/1819-6446-2017-13-5-645-650
4. Еганян Р.А. Роль неалкогольной жировой болезни печени в развитии сердечно-сосудистых заболеваний. CardioСоматика. 2018; 9(1):47-53.
5. Журавлева Л.В., Огнева Е.В., Власенко А.В. Роль резистина и гомоцистеина в прогрессировании функциональных нарушений печени у больных с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2019;(8):11-15. https://doi.org/10.31146/1682-8658-ecg-168-8-11-15
6. Мязин Р.Г. НАЖБП и сердечно-сосудистые риски: клиника, диагностика, особенности терапии. Медицинский совет. 2019;12:82-86. DOI: https://doi.org/10.21518/2079-701X-2019-12-82-86.
7. Хамраев А.А., Юлдашева Д. Клинические, лабораторные и молекулярно-генетические маркеры прогрессии неалкогольной жирной болезни печени (обзор литературы и собственные данные). //Общество и инновации. 2021;2:399-406. doi.org/10.47689/2181-1415-vol2-iss2/S-pp399-406.
8. Bhatia L, Scorletti E, Curzen N, et al. Improvement in nonalcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis. 2016; 246:13-20. doi: 10.1016/j.atherosclerosis.2015.12.028
9. Bonci E, Chiesa C, Versacci P, et al. Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015:213737. doi: 10.1155/2015/213737
10. Cazac GD, Lăcătușu CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. Life (Basel). 2022 Aug 4;12(8):1189. doi: 10.3390/life12081189.
11. Dai H, Wang W, Tang X, et al. Association between homocysteine and non-alcoholic fatty liver disease in Chinese adults: a cross-sectional study. //Nutr J. 2016;15(1):102.
12. de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clin Nutr. 2017 Jan 19. pii: S0261-5614(17)30011-0. doi: 10.1016/j.clnu.2017.01.006.
13. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388-402.
14. Fargion S., Porzio M., Fracanzani A.L. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art // World J Gastroenterology. 2014;20:13306-13324.
15. Francque S.M.,van der Graaff D., Kwanten W.J. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications //J Hepatol,  2016;65:425-443.
16. Kim H.S., Cho Y.K. Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease. //Korean J Gastroenterol. 2017 Jun 25;69(6):333-340. Korean. doi: 10.4166/kjg.2017.69.6.333.
17. Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021 Jul;110(7):921-937. doi: 10.1007/s00392-020-01709-7.
18. Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E. Lipoprotein(a)—An independent causal risk factor for cardiovascular disease and current therapeutic options. //Atheroscler Suppl. 2015;18:263-7. doi: 10.1016/j.atherosclerosissup.2015.02.039.
19. Ma M, Duan R, Zhong H, et al. The Crosstalk between Fat Homeostasis and Liver Regional Immunity in NAFLD. J Immunol Res. 2019;3954890. doi: https://doi.org/10.1155/2019/3954890
20. Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. //Lancet Gastroenterol Hepatol. 2021 Nov;6(11):903-913. doi: 10.1016/S2468-1253(21)00308-3.